Poseida’s CAR T-cell Therapy Eradicates Previously Incurable Prostate Cancer in Mice

Poseida’s CAR T-cell Therapy Eradicates Previously Incurable Prostate Cancer in Mice
Poseida Therapeutics’ CAR T-cell therapy P-PSMA-101 eradicated a previously incurable type of human prostate cancer implanted in mice, the company reported. Another CAR T-cell therapy that has reached doctor's offices has failed to counter the cancer, researchers said. The implication was that the improvements Poseida has introduced make a difference. Poseida’s founder and CEO, Eric Ostertag, presented the findings of the preclinical-trial study at the 24th Prostate Cancer Foundation Annual Retreat in Washington. It started Oct. 5 and ends Oct. 7. “We are impressed that P-PSMA-101 was able to eliminate tumors beyond the limit of detection using an aggressive cancer cell line that was previously incurable with other treatment modalities,” Ostertag said in a press release. The PSMA part of the product name is short for prostate-specific membrane antigen — a molecule found on the surface of most prostate cancer cells. P-PMSA-101's genetically modified T-cells target this molecule to fight the cancer. CAR T-cell therapy involves using a patient's immune T-cells to fight cancer. The first step is harvesting T-cells from a patient. Medical professionals genetically alter them so they can fight a cancer better and multiply them before injecting them back into the patient. Poseida has made changes in the way the T-cells are engineered. It has also introduced modifications that make the cells
Subscribe or to access all post and page content.